Abstract:
The most common endocrine tumor is thyroid carcinoma (TC). The clinical
significance of thyroid carcinoma with respect to the recurrence of the disease state
has been reviewed recently. Current therapy includes surgery (thyroidectomy) and
radiotherapy that are not affordable and may indicate the risk of relapse. Although
there are drugs available in the market; however, side-effects and drug-resistance
limit their full potential to be used. Since the expression analysis identifies important
cellular processes or metabolic pathways which are important during the phase of
infection. Therefore, identifying effective therapeutic targets through microarray and
high throughput sequencing technology might serve a purpose in the treatment of the
thyroid carcinoma in its early stages. In order to achieve the objectives of the study,
Microarray and RNA-seq data analysis have been performed. We analyzed different
datasets of thyroid carcinoma induced in order to find similarities and differences
between expression profiles. After identification of expression level of mRNAs and
miRNAs, targets of miRNAs are also predicted. The data analysis has revealed 36
common differentially expressed genes (DEGs) for thyroid carcinoma. Out of these
genes, only (Zinc finger and BTB domain containing protein 44) ZBTB44 is not
considered a prognostic therapeutic target for thyroid cancer but for other carcinomas
patients in literature, which needs further investigation to overcome the disease. While
remaining differentially expressed genes are also validated through literature review.
Pathway analysis is then performed on the all DEGs that shows their involvement
in following pathways; Proteoglycans in cancer, Transcriptional misregulation in
cancer, PI3K-AKT signaling pathway, WNT signalling pathway and MAPK signaling
pathway. This study can provide the basis for further validation through systems
biology approach and wet lab techniques.
